Novel PVA-Based Hydrogel Microparticles for Doxorubicin DeliveryFrancesca Cavalieri, Gaio Paradossi, Ester Chiessi et al.|Biomacromolecules|2008Cited by 96
Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cellsRaffaella Villa, Nadia Zaffaroni, Barbara Cerroni et al.|Colloids and Surfaces B Biointerfaces|2013Cited by 57
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Giampaolo Bianchini, Marina Ferrarini et al.|Nature Communications|2025Cited by 5
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.Giampaolo Bianchini, Luca Gianni, Matteo Dugo et al.|Journal of Clinical Oncology|2021Cited by 1